Investor Presentation First Nine Months of 2023

10 Investor presentation First nine months of 2023 Rare disease sales decreased by 18% driven by temporary reduction in manufacturing output Reported Rare disease sales Rare disease sales driven by global commercial execution DKK billion Growth at CER Rare disease sales decrease is driven by: 15 -18% 2% 15% 44% -5% -54% • 13% sales decline in North America Operations 12 9 Rare blood disorders 6 3 Novo NordiskⓇ • 22% sales decline in International Operations Rare blood disorders sales increased by 2%, driven by: . • Launch products in haemophilia A and B, partially countered by NovoSevenⓇ Rare endocrine disorders sales decreased by 54% driven by: Sales for Norditropin® declined by 50% in NAO and 56% in IO, reflecting a temporary reduction in manufacturing output Novo Nordisk has a value market share of 24.6% in the global human growth disorder market 0 Total1 Rare blood Haem. A Haem. B Novo- ! SevenⓇ disorders² Rare endocrine disorders³ 1Total includes "Other Rare disease", which consists of primarily Vagifem® and ActivelleⓇ: 2Comprises NovoSeven®, Novo Eight®, Esperoct®, Refixia® and NovoThirteenⓇ; 3 Primarily Norditropin® CER: Constant exchange rates; Haem. A: Haemophilia A; Haem. B: Haemophilia B; NAO: North America operations; IO: International operations; Unless otherwise specified, sales growth is at constant exchange rates Note: NovoThirteenⓇ is not shown for Rare blood disorders breakdown, only for the total bar.

View entire presentation